ReviewThe Annals of thoracic surgery2024
The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer.
Review in The Annals of thoracic surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Use of PD-1/PD-L1 inhibitors in non-small cell lung cancer in elderly patients: a meta-analysis and systematic review of randomized clinical trials.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Pooled it
- Management of borderline resectable NSCLC: a narrative review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Treatment patterns and outcomes of later-line therapy in advanced non-small cell lung cancer with unknown or no actionable genomic alterations: a multicenter real-world study in China (RECAP study).Translational lung cancer research · 2026Article
- Immune-preserving radiotherapy and perioperative immunotherapy in stage III NSCLC: a narrative review of current management and future directions for IIIA/IIIB NSCLC.Translational lung cancer research · 2026Review
- Efficacy of Bioengineered PD-L1 siRNA for Immunotherapy Against Non-Small Cell Lung Cancer Cells.Non-coding RNA · 2026Article
- Perioperative Systemic Therapies in Resectable Non-Small Cell Lung Cancer: Opportunities and Challenges.Journal of clinical medicine · 2026Review
- Post-operative outcomes of lung resection after perioperative chemoimmunotherapy for stage IIB-IIIB non-small-cell lung cancer in the elderly: a single center real-life experience.Journal of thoracic disease · 2026Article
- The Interplay of Preoperative Sarcopenia, Systemic Inflammation, and Neoadjuvant Therapy in Resectable NSCLC-Identifying the Gap: A Narrative Review of Surgical and Oncological Outcomes.Medicina (Kaunas, Lithuania) · 2026Review
- Adjuvant chemotherapy for completely resected stage IB-IIA non-small cell lung cancer according to the AJCC 8th edition staging system: a real-world retrospective cohort study based on the SEER database.Translational lung cancer research · 2026Article
- Article
- The Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer.Oncology research · 2026Review
- c-MET expression and immune landscape in locally advanced patients with non-small cell lung cancer undergoing radiochemotherapy and consolidative immunotherapy.Translational lung cancer research · 2025Article
- The Evolving Interplay Between Targeted Therapy and Surgery for Resectable Lung Cancer.Cancers · 2025Review
- The impact of preoperative percutaneous transthoracic needle biopsy on pleural recurrence in clinically early-stage non-small cell lung cancer.Journal of thoracic disease · 2025Article
- Robotic-assisted bronchoscopy for histopathologic subtyping of primary lung adenocarcinoma.Lung cancer (Amsterdam, Netherlands) · 2025Article
- MED12-STAT1-TAP2 axis regulates CD8 + T cell cytotoxicity and mediates immunotherapy outcome in non-small cell lung cancer.Functional & integrative genomics · 2025Article
- Malignant pleural effusion is a negative prognostic factor for immunotherapy outcomes in non-small cell lung cancer: a single-center retrospective study.Journal of thoracic disease · 2025Article
- Real-world treatment patterns and outcomes for patients with non-metastatic non-small cell lung cancer: retrospective analyses in Canada, England, and Germany.BMC pulmonary medicine · 2025Article
- Perioperative immunotherapy strategies for resectable non-small cell lung cancer.The Cochrane database of systematic reviews · 2025Article
- Prognostic Significance, Radiological, and Metabolic Characteristics of Metastatic Lymph Nodes in Resectable Non-Small Cell Lung Cancer Following Neoadjuvant Chemoimmunotherapy.Thoracic cancer · 2025Article
Corrections and comments
- Commented on by
Authors and funding
18 authors at 6 institutions in 2 countries.
Funding
Abstract
backgroundDespite surgical resection, long-term survival of patients with resectable non-small cell lung cancer (NSCLC) remains poor. Adjuvant chemotherapy, the standard of care for locally advanced NSCLC, provides a marginal 5.4% benefit in survival. Immune checkpoint inhibitors (ICIs) have shown a significant survival benefit in some patients with advanced NSCLC and are being evaluated for perioperative use in resectable NSCLC.
methodsWe conducted a literature search using the PubMed online database to identify clinical trials of immunotherapy in resectable NSCLC and studies analyzing biomarkers and immune priming strategies.
resultsBuilding on previous phase I and II trials, randomized phase III trials have shown efficacy of neoadjuvant nivolumab, perioperative pembrolizumab, adjuvant atezolizumab, and adjuvant pembrolizumab in the treatment of NSCLC with improvement of event-free/disease-free survival of 24% to 42%, leading to United States Food and Drug Administration approval of these drugs in the treatment of resectable NSCLC. Three additional phase III trials have also recently reported the use of immunotherapy both before and after surgery, with pathologic complete response rates of 17% to 25%, significantly better than chemotherapy alone. Perioperative ICI therapy has comparable perioperative morbidity to chemotherapy alone and does not impair surgical outcomes.
conclusionsPerioperative immunotherapy, in combination with chemotherapy, is safe and improves outcomes in patients with resectable NSCLC. Questions regarding patient selection, the need for adjuvant ICI therapy after neoadjuvant chemoimmunotherapy, and the duration of perioperative immunotherapy remain to be answered by future trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.